Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Recro Pharma Inc (REPH)

Recro Pharma Inc (REPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,627
  • Shares Outstanding, K 23,640
  • Annual Sales, $ 99,220 K
  • Annual Income, $ -18,630 K
  • 60-Month Beta 0.54
  • Price/Sales 0.56
  • Price/Cash Flow 4.08
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -10.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.04 +21.57%
on 09/08/20
2.97 -16.50%
on 08/19/20
-0.43 (-14.78%)
since 08/18/20
3-Month
2.04 +21.57%
on 09/08/20
5.04 -50.79%
on 06/23/20
-2.35 (-48.65%)
since 06/18/20
52-Week
2.04 +21.57%
on 09/08/20
19.21 -87.09%
on 02/13/20
-9.24 (-78.84%)
since 09/18/19

Most Recent Stories

More News
Recro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of...

MHMNF : 54.5000 (unch)
REPH : 2.48 (+5.98%)
Recro Pharma: 2Q Earnings Snapshot

MALVERN, Pa. (AP) _ Recro Pharma Inc. (REPH) on Monday reported a loss of $6 million in its second quarter.

REPH : 2.48 (+5.98%)
Recro Reports Second Quarter 2020 Financial Results

Launches Clinical Trial Materials Business and Secures New Customers

REPH : 2.48 (+5.98%)
Recro to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020

Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for development, formulation, regulatory support, manufacturing and packaging...

REPH : 2.48 (+5.98%)
Recro Highlights Manufacturing Readiness For Essential Drugs and Medical Supplies

Company Owns and Operates Over 120,000 Square Feet of U.S. cGMP and DEA-Licensed Contract Development and Manufacturing Facilities Focused on Creating Oral, Solid Dose Drug Products

REPH : 2.48 (+5.98%)
Recro Pharma (REPH) in Focus: Stock Moves 7.6% Higher

Recro Pharma (REPH) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

REPH : 2.48 (+5.98%)
ATXI : 11.50 (+3.05%)
RECRO PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating Recro Pharma, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Recro Pharma, Inc. (NASDAQ: REPH) on behalf of Recro Pharma stockholders. Our...

REPH : 2.48 (+5.98%)
INVESTOR ALERT: Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Recro Pharma, Inc.

The law firm of Kirby McInerney LLP is investigating potential claims against Recro Pharma, Inc. ("Recro Pharma" or the "Company") (NASDAQ: REPH). This investigation concerns whether Recro Pharma has violated...

REPH : 2.48 (+5.98%)
Recro Pharma, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton; Investors Who Lost Money Should Contact the Firm

Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that it has launched an investigation into potential securities fraud by Recro Pharma Inc. (NASDAQ: REPH) and certain...

REPH : 2.48 (+5.98%)
Investor Alert: Kaplan Fox Investigates Recro Pharma, Inc.

, /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP () is investigating claims on behalf of investors of Recro Pharma, Inc. ("Recro Pharma" or the "Company") (NASDAQ: REPH).  Investors who purchased Recro...

REPH : 2.48 (+5.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade REPH with:

Business Summary

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough...

See More

Key Turning Points

2nd Resistance Point 2.65
1st Resistance Point 2.56
Last Price 2.48
1st Support Level 2.36
2nd Support Level 2.24

See More

52-Week High 19.21
Fibonacci 61.8% 12.65
Fibonacci 50% 10.63
Fibonacci 38.2% 8.60
Last Price 2.48
52-Week Low 2.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar